{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:39:11Z","timestamp":1790807951008,"version":"4.1.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:p>Rosai\u2013Dorfman disease (RDD), juvenile xanthogranuloma (JXG), and Erdheim\u2013Chester disease (ECD) are non-Langerhans cell (non-LCH) disorders arising from either a dendritic or a macrophage cell. RDD is a benign disorder that presents with massive lymphadenopathy, but can have extranodal involvement. In most cases, RDD is self-limited and observation is the standard approach. Treatment is restricted to patients with life-threatening, multiple-relapsing, or autoimmune-associated disease. JXG is a pediatric histiocytosis characterized by xanthomatous skin lesions that usually resolve spontaneously. In a minority of cases, systemic disease can occur and can be life threatening. Juvenile myelomonocytic leukemia (JMML), as well as germline mutations in NF1 and NF2, have been reported in children with JXG. Recent whole-exome sequencing of JXG cases did not show the BRAF-V600E mutation, although 1 patient had PI3KCD mutation. ECD is an adult histiocytosis characterized by symmetrical long bone involvement, cardiovascular infiltration, a hairy kidney, and retroperitoneal fibrosis. Central nervous system involvement is a poor prognostic factor. Interferon-\u03b1 is the standard as front-line therapy, although cladribine and anakinra can be effective in a few refractory cases. More than one-half of ECD patients carry the BRAF-V600E mutation. Currently, &gt;40 patients worldwide with multisystemic, refractory BRAF-V600E+ ECD have been treated with vemurafenib, a BRAF inhibitor, which was found to be highly effective. Other recurrent mutations of the MAP kinase and PI3K pathways have been described in ECD. These discoveries may redefine ECD, JXG, and LCH as inflammatory myeloid neoplasms, which may lead to new targeted therapies.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.571","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"571-578","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":79,"title":["Uncommon histiocytic disorders: Rosai\u2013Dorfman, juvenile xanthogranuloma, and Erdheim\u2013Chester disease"],"prefix":"10.1182","volume":"2015","author":[{"given":"Julien","family":"Haroche","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and French reference Center for Rare Auto-immune and Systemic Diseases, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France;"},{"name":"Universit\u00e9 Pierre et Marie Curie, UPMC University Paris 6, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama","family":"Abla","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111706103376900_B1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/pbc.20246","article-title":"Uncommon histiocytic disorders: the non-langerhans cell histiocytoses","volume":"45","author":"Weitzman","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2019111706103376900_B2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1172\/JCI32282","article-title":"Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages","volume":"117","author":"Zaba","year":"2007","journal-title":"J Clin Invest"},{"key":"2019111706103376900_B3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/CBO9780511545252.016","article-title":"Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses","volume-title":"Histiocytic Disorders of Children and Adults","author":"Weitzman","year":"2005"},{"issue":"1","key":"2019111706103376900_B4","first-page":"19","article-title":"Sinus hisitocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity","volume":"7","author":"Foucar","year":"1990","journal-title":"Semin Diagn Pathol"},{"issue":"11 Pt 2","key":"2019111706103376900_B5","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.lpm.2007.06.008","article-title":"Rosai\u2013Dorfman disease [in French]","volume":"36","author":"Galicier","year":"2007","journal-title":"Presse Med"},{"issue":"6","key":"2019111706103376900_B6","first-page":"1169","article-title":"Ad\u00e9nites avec surcharge lipidique, de l'enfant ou de l'adulte jeune, observ\u00e9es aux Antilles et au Mali","volume":"58","author":"Destombes","year":"1965","journal-title":"Bull Soc Pathol Exot"},{"issue":"1","key":"2019111706103376900_B7","first-page":"63","article-title":"Sinus histiocytosis with massive lymphadenopathy","volume":"87","author":"Rosai","year":"1969","journal-title":"Arch Pathol"},{"issue":"5","key":"2019111706103376900_B8","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/1097-0142(197211)30:5<1174::AID-CNCR2820300507>3.0.CO;2-S","article-title":"Sinus histiocytosis with massive lymphadenopathy: a pseudolymphomatous benign disorder: analysis of 34 cases","volume":"30","author":"Rosai","year":"1972","journal-title":"Cancer"},{"issue":"7","key":"2019111706103376900_B9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/pbc.25017","article-title":"Updates on histiocytic disorders","volume":"61","author":"Vaiselbuh","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2019111706103376900_B10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.pas.0000157997.61177.08","article-title":"Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome","volume":"29","author":"Maric","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2019111706103376900_B11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.20605","article-title":"Faisalabad histiocytosis mimics Rosai\u2013Dorfman disease: brothers with lymphadenopathy, intrauterine fractures, short stature and sensorineural deafness","volume":"47","author":"Rossbach","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2019111706103376900_B12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/DAD.0b013e3181ee547c","article-title":"A case of H syndrome showing immunophenotype similarities to Rosai\u2013Dorfman disease","volume":"33","author":"Avitan-Hersh","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"2019111706103376900_B13","doi-asserted-by":"crossref","article-title":"La maladie de Rosai\u2013Dorfman-Destombes est une histiocytose inflammatoire polymorphe: \u00e9tude ph\u00e9notypique multicentrique de 47 patients","author":"Cohen-Aubart","DOI":"10.1016\/j.revmed.2015.03.267"},{"issue":"19","key":"2019111706103376900_B14","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111706103376900_B15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.10008","article-title":"Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review","volume":"69","author":"Pulsoni","year":"2002","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111706103376900_B16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0190-9622(97)70186-5","article-title":"Sinus histiocytosis with massive lymphadenopathy: presentation as giant granuloma annulare and detection of human herpesvirus 6","volume":"37","author":"Scheel","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2019111706103376900_B17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/archderm.143.6.736","article-title":"Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses","volume":"143","author":"Utikal","year":"2007","journal-title":"Arch Dermatol"},{"issue":"1","key":"2019111706103376900_B18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12185-008-0192-2","article-title":"Extranodal multifocal Rosai\u2013Dorfman disease: response to 2-chlorodeoxyadenosine treatment","volume":"89","author":"Konca","year":"2009","journal-title":"Int J Hematol"},{"issue":"3","key":"2019111706103376900_B19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pbc.24772","article-title":"Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease","volume":"61","author":"Simko","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"37","key":"2019111706103376900_B20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1055\/s-2001-17109","article-title":"\u201cCatastrophic systemic lupus erythematous\u201d with Rosai-Dorfman sinus histiocytosis: successful treatment with anti-CD20\/rituximab","volume":"126","author":"Petschner","year":"2001","journal-title":"Dtsch Med Wochenschr"},{"issue":"3","key":"2019111706103376900_B21","first-page":"475","article-title":"The confusing state of the histiocytoses","volume":"143","author":"Chu","year":"2000","journal-title":"Br J Dermatol"},{"issue":"1","key":"2019111706103376900_B22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.pas.0000147395.01229.06","article-title":"Juvenile xanthogranuloma in childhood and adolescence: a clinicopathological study of 129 patients from the Kiel pediatric tumor registry","volume":"29","author":"Janssen","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2019111706103376900_B23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000478-200305000-00003","article-title":"Juvenile xanthogranuloma in the first two decades of life: a clinicopathological study of 174 cases with cutaneous and extracutaneous manifestations","volume":"27","author":"Dehner","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2019111706103376900_B24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/pbc.21830","article-title":"Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine","volume":"52","author":"Rajendra","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2019111706103376900_B25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.braindev.2007.07.004","article-title":"Subdural effusion in a CNS involvement of systemic juvenile xanthogranuloma: a case report treated with vinblastine","volume":"30","author":"Auvin","year":"2008","journal-title":"Brain Dev"},{"issue":"1","key":"2019111706103376900_B26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.21523","article-title":"Treatment of juvenile xanthogranuloma","volume":"51","author":"Stover","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2019111706103376900_B27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/pbc.23087","article-title":"Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain","volume":"58","author":"Yamada","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"2019111706103376900_B28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/BF01942684","article-title":"\u00dcber Lipoidgranulomatose","volume":"279","author":"Chester","year":"1930","journal-title":"Virchows Arch Pathol Anat"},{"issue":"3","key":"2019111706103376900_B29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00005792-199605000-00005","article-title":"Erdheim-Chester disease: clinical and radiologic characteristics of 59 cases","volume":"75","author":"Veyssier-Belot","year":"1996","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2019111706103376900_B30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/BOR.0b013e32834d861d","article-title":"Erdheim-Chester disease","volume":"24","author":"Haroche","year":"2012","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"2019111706103376900_B31","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","article-title":"CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111706103376900_B32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","article-title":"Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease","volume":"124","author":"Diamond","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111706103376900_B33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.md.0000145368.17934.91","article-title":"Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review","volume":"83","author":"Haroche","year":"2004","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"2019111706103376900_B34","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111706103376900_B35","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses","volume":"120","author":"Haroche","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111706103376900_B36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","article-title":"Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease","volume":"33","author":"Haroche","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111706103376900_B37","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","article-title":"Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease","volume":"124","author":"Emile","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111706103376900_B38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","article-title":"Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation","volume":"124","author":"Hervier","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111706103376900_B39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.13247","article-title":"Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?","volume":"169","author":"Berres","year":"2015","journal-title":"Br J Haematol"},{"issue":"16","key":"2019111706103376900_B40","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1200\/JCO.2010.34.0307","article-title":"Scintigraphic diagnosis of Erdheim-Chester disease","volume":"29","author":"Balink","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111706103376900_B41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000046267","article-title":"Two enlarged kidneys: a manifestation of Erdheim-Chester disease","volume":"21","author":"Andre","year":"2001","journal-title":"Am J Nephrol"},{"issue":"11 Pt 2","key":"2019111706103376900_B42","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.lpm.2007.04.032","article-title":"[Erdheim-Chester disease]","volume":"36","author":"Haroche","year":"2007","journal-title":"Presse Med"},{"issue":"25","key":"2019111706103376900_B43","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1161\/CIRCULATIONAHA.108.825075","article-title":"Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients","volume":"119","author":"Haroche","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"2019111706103376900_B44","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0022-5347(05)68107-4","article-title":"Bilateral hydronephrosis in a patient with Erdheim-Chester disease","volume":"162","author":"Droupy","year":"1999","journal-title":"J Urol"},{"issue":"10","key":"2019111706103376900_B45","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00415-006-0160-9","article-title":"Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature","volume":"253","author":"Lachenal","year":"2006","journal-title":"J Neurol"},{"issue":"9","key":"2019111706103376900_B46","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harbouring the BRAF V600E mutation","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111706103376900_B47","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood-2005-06-2238","article-title":"Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha","volume":"106","author":"Braiteh","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111706103376900_B48","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/art.22165","article-title":"Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients","volume":"54","author":"Haroche","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2019111706103376900_B49","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","article-title":"Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial","volume":"126","author":"Gianfreda","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2019111706103376900_B50","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/WNL.0000000000000832","article-title":"Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease","volume":"83","author":"Cohen-Aubart","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"2019111706103376900_B51","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood-2013-02-482984","article-title":"Detection of an NRAS mutation in Erdheim-Chester disease","volume":"122","author":"Diamond","year":"2013","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/571\/65493\/bep00115000571.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/571\/65493\/bep00115000571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T11:11:07Z","timestamp":1573989067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/571\/20637\/Uncommon-histiocytic-disorders-RosaiDorfman"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.571","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}